Adjuvant Chemo-Immuno-Therapy with LMF+BCG in Node-Negative and Node-Positive Breast Cancer

Senn, Hans; Jungi, W. F.; Amgwerd, R; Sprenger, F; Hochuli, E; Engelhart, G. J.; Heinz, C; Wick, A; Enderlin, F; Simeon, B.; Lanz, R; Bigler, Robert D.

doi:10.1007/978-3-642-67111-1_5

Cited by 3 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the addition of BCG to CMF plus tamoxifen did not further diminish recurrences. Senn and associates [17] showed no beneficial effect of adjuvant chemo-immunotherapy with chlorambucil, methotrexate, and 5-FU plus BCG in 242 patients.…”

Section: Discussionmentioning

confidence: 98%

Adjuvant chemo‐lmmunotherapy in stage II carcinoma of the breast

Giuliano

Sparks

Patterson

et al. 1986

Journal of Surgical Oncology

View full text Add to dashboard Cite

From July of 1974 to June of 1978, 131 patients with Stage II carcinoma of the breast were randomly assigned to one of three treatment arms in order to assess the efficacy of adding immunotherapy to adjuvant chemotherapy. All patients had metastases in the axillary lymph nodes, but no clinical evidence of systemic disease. Prognostic factors were relatively equally distributed among the three treatment arms. All patients received adjuvant chemotherapy consisting of cytoxan, methotrexate, and 5-fluorouracil (CMF). In addition, patients received adjuvant immunotherapy consisting of Bacille Calmette Guerin (BCG) or BCG plus a tumor cell vaccine. This vaccine was a mixture of allogeneic breast cancer cell lines grown in tissue culture. Fourteen patients receiving tumor cell vaccine developed hepatitis B, leading to the abandonment of this arm of the study. Side effects of chemotherapy were tolerable. No statistically significant difference could be demonstrated in recurrence rate or survival. However, the two groups receiving adjuvant chemo-immunotherapy had a slightly shorter time to recurrence and lower overall survival. The use of chemo-immunotherapy as administered in this study did not improve the clinical course of patients with Stage II breast cancer and was associated with significant morbidity.

show abstract

Section: Discussionmentioning

confidence: 98%

Adjuvant chemo‐lmmunotherapy in stage II carcinoma of the breast

Giuliano

Sparks

Patterson

et al. 1986

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…The ability of adjuvant chemotherapy to improve relapse-free survival in premenopausal women with stage II breast cancer has been demonstrated in a number of randomized clinical studies (1,2,3,4,5,6,7). From other studies it would appear that polychemotherapy is more efficient than monoolrug therapy with alkylating agents (2,3,8,9), but the only alkylating agent which has been evaluated in comparative trials is melphalan given orally.…”

Section: Introductionmentioning

confidence: 94%

Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer

Brincker

Mouridsen²,

Andersen³

1983

Breast Cancer Res Tr

View full text Add to dashboard Cite

After total mastectomy and partial axillary dissection, 805 premenopausal women with stage II breast cancer were randomized to receive postoperative radiotherapy (RT) alone, RT + cyclophosphamide (C) for 12 monthly cycles, or RT + cyclophosphamide/methotrexate/5-fluorouracil (CMF) for 12 monthly cycles. At 3 years actuarial relapse-free survival for RT + C and RT + CMF was significantly better than for RT alone (p = 0.0009 and 0.0001, respectively). There was no significant difference in relapse-free survival between RT + C and RT + CMF. C resulted in more pronounced haematologic toxicity and a higher frequency of amenorrhoea and of alopecia than CMF, while CMF resulted in more pronounced nausea and stomatitis than C. In the preliminary results, C alone may be as effective as CMF in prolonging relapse-free survival in premenopausal women with stage II breast cancer.

show abstract

“…In 1974 an adjuvant study which included both node negative and positive women with T 1 _ 3A lesions was initiated by the OSAKO Group in Switzerland [23]. A total of 241 evaluable patients were randomized to receive surgery only, with a modified radical mastectomy, or surgery plus LMF + BCG.…”

Section: Clinical Trialsmentioning

confidence: 99%

Review : Adjuvant use of cytotoxic chemotherapy to destroy micrometastasis in breast cancer after local control therapy?current status

Carter

1983

Clin Exp Metast

View full text Add to dashboard Cite

Adjuvant Chemo-Immuno-Therapy with LMF+BCG in Node-Negative and Node-Positive Breast Cancer

Cited by 3 publications

References 18 publications

Adjuvant chemo‐lmmunotherapy in stage II carcinoma of the breast

Adjuvant chemo‐lmmunotherapy in stage II carcinoma of the breast

Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer

Review : Adjuvant use of cytotoxic chemotherapy to destroy micrometastasis in breast cancer after local control therapy?current status

Contact Info

Product

Resources

About